

# A A Shabalina

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2205293/publications.pdf>

Version: 2024-02-01

18  
papers

78  
citations

1684188  
5  
h-index

1588992  
8  
g-index

24  
all docs

24  
docs citations

24  
times ranked

67  
citing authors

#	ARTICLE	IF	CITATIONS
1	MicroRNA as significant biomarkers of cerebrovascular atherosclerosis. <i>Annals of Clinical and Experimental Neurology</i> , 2022, 16, 5-13.	0.4	2
2	Monitoring of Aspirin Therapy in Patients with Cerebrovascular Pathology. <i>Rational Pharmacotherapy in Cardiology</i> , 2021, 17, 537-543.	0.8	1
3	Resolved and unresolved issues of cerebrovascular disease in diabetes mellitus. <i>Annals of Clinical and Experimental Neurology</i> , 2021, 15, 5-14.	0.4	4
4	MRI Types of Cerebral Small Vessel Disease and Circulating Markers of Vascular Wall Damage. <i>Diagnostics</i> , 2020, 10, 354.	2.6	8
5	Formalised assessment of systemic thrombogenicity in patients with Polycythemia vera suffered an ischemic stroke. <i>Atherothrombosis</i> , 2020, , 105-114.	0.3	1
6	Ischemic stroke in menopausal women: hemorheological parameters and structural and functional changes of the vascular wall. <i>Tromboz, Gemostaz I Reologiya</i> , 2020, , .	0.2	0
7	Tissue Plasminogen Activator and MRI Signs of Cerebral Small Vessel Disease. <i>Brain Sciences</i> , 2019, 9, 266.	2.3	10
8	Use of Gas Chromatomass Spectroscopy for Analysis of Salicylate Contents in Plasma from Patients with Cerebrovascular Diseases Taking Aspirin as Antiaggregant Therapy. <i>Pharmaceutical Chemistry Journal</i> , 2019, 53, 65-70.	0.8	5
9	Lipid Peroxidation Products in the Blood Plasma of Patients with Parkinsonâ€™s Disease as Possible Biomarkers of Different Stages of the Disease. <i>Neurochemical Journal</i> , 2019, 13, 391-395.	0.5	9
10	The comparison between two methods of laboratory evaluation for platelet aggregation and for resistance to antiplatelet therapy. <i>Tromboz, Gemostaz I Reologiya</i> , 2019, , .	0.2	0
11	Antiangiogenic effects of acetylsalicylic acid in patients with polycythemia vera. <i>Tromboz, Gemostaz I Reologiya</i> , 2019, , .	0.2	0
12	Prevention of Cerebrovascular Disease in Patients with Myeloproliferative Disorders. <i>Human Physiology</i> , 2018, 44, 896-900.	0.4	0
13	Neovascularization of Carotid Atherosclerotic Plaque and Quantitative Methods of Its Dynamic Assessment in Vivo. <i>Bulletin of Experimental Biology and Medicine</i> , 2018, 165, 521-525.	0.8	2
14	Multimodal approach to treatment of neurological complications of chronic brain ischemia. <i>Terapevticheskii Arkhiv</i> , 2018, 90, 61-67.	0.8	5
15	Clinical Characteristics of Cerebrovascular Pathology with Patients Suffering from Ph-Negative Myeloproliferative Disease. <i>Cerebrovascular Diseases Extra</i> , 2017, 6, 66-70.	1.5	11
16	In vitro lipid-lowering and fibrinolytic effects of regulatory leucine-containing glyprolines in human blood. <i>Biology Bulletin</i> , 2015, 42, 74-77.	0.5	7
17	Estimation of Functional Activity of Ionized Calcium for Complement System Reactivity Assessment. <i>Bulletin of Experimental Biology and Medicine</i> , 2015, 159, 305-308.	0.8	0
18	Modulators of cystein proteases and cell-death markers in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis. <i>Neurochemical Journal</i> , 2009, 3, 133-138.	0.5	1